Abstract:Arteriosclerosis and its complications, such as heart attack and stroke, are the major causes of death in developed countries. It was believed that age, hyperlipidemia, hypertension, diabetes and smoking are common risk factors for cardiovascular disease. In addition, overwhelming clinical and epidemiological studies have identified homocysteine (Hcy) as a significant and independent risk factor for cardiovascular disease. In healthy individuals, plasma Hcy is between 5 and 10 micromol/L. One cause of severe hypehomocys- teinemia (HHcy) is the deficiency of cystathionine beta-synthase (CBS), which converts Hcy to cystathionine. CBS homozygous deficiency results in severe HHcy with Hcy levels up to 100 to 500 micromol/L. Patients with severe HHcy usually present with neurological abnormalities, premature arteriosclerosis. It has been reported that lowering plasma Hcy improved endothelial dysfunction and reduced incidence of major adverse events after percutaneous coronary intervention. The mechanisms by which Hcy induces atherosclerosis are largely unknown. Several biological mechanisms have been proposed to explain cardiovascular pathological changes associated with HHcy. These include: (1) endothelial cell damage and impaired endothelial function; (2) dysregulation of cholesterol and triglyceride biosynthesis; (3) stimulation of vascular smooth muscle cell proliferation; (4) thrombosis activation and (5) activation of monocytes. Four major biochemical mechanisms have been proposed to explain the vascular pathology of Hcy. These include: (1) autooxidation through the production of reactive oxygen species; (2) hypomethylation by forming SAH, a potent inhibitor of biological transmethylations; (3) nitrosylation by binding to nitric oxide or (4) protein homocysteinylation by incorporating into protein. In summary, our studies, as well as data from other laboratories support the concept that Hcy is causally linked to atherosclerosis, and is not merely associated with the disease. Although folic acid, vitamin B12 and B6 can lower plasma Hcy levels, the long-term effects on cardiovascular disease risk are still unknown and judgments about therapeutic benefits await the findings of ongoing clinical trials.

Hyperhomocysteinemia and Erectile Dysfunction: an Update

Clinical Significance of Plasma Homocysteine in the Coronary Atherosclerosis Patients

Association between serum homocysteine and erectile dysfunction: a systematic review and meta-analysis

Age-Dependent Effects of Homocysteine on Erectile Dysfunction Risk Among U.S. Males: A NHANES Analysis

Association Between Homocysteine, Vitamin B12, Folic Acid and Erectile Dysfunction: a Cross-Sectional Study in China

Relationship between content of Hcy and incidence rate of ED in young male hypertensives

Hyperhomocysteinaemia in Rats is Associated with Erectile Dysfunction by Impairing Endothelial Nitric Oxide Synthase Activity.

Association Between Folic Acid, Homocysteine, Vitamin B12 and Erectile Dysfunction—a Cross‐sectional Study

Advances in Research in Relationship Between Hyperhomocysteinemia and Coronary Heart Disease

Hyperuricemia is an Independent Risk Factor for Erectile Dysfunction

[Research Advances in the Treatment of Hyperhomocysteinemia].

[Update of the Relationship Between Erectile Dysfunction and Endothelial Function].

Updating the relationship between hyperhomocysteinemia lowering therapy and cardiovascular events.

Hyperhomocysteinemia and Vascular Injury: The Advance of Mechanisms and Drug Targets

Homocysteine impaired endothelial function via compromised VEGF/Akt/eNOS signaling (Revised 1)

Mechanism of homocysteine-mediated endothelial injury and its consequences for atherosclerosis

Homocysteine impairs coronary artery endothelial function by inhibiting tetrahydrobiopterin in patients with hyperhomocysteinemia.

Hyperhomocysteinemia and atherosclerosis

Hyperuricemia: A key contributor to endothelial dysfunction in cardiovascular diseases

Cardiovascular pathogenesis in hyperhomocysteinemia

Hyperhomocysteinemia and Hyperlipidemia in Coronary Heart Disease.